Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Luye Pharma Group Ltd. clinical trials
Also known as AsiaPharm.
The registry lists 94 studies whose lead sponsor is Luye Pharma Group Ltd. or one of 4 companies grouped under it. 20 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Luye Pharma Group Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Luye Pharma Group Ltd..
- Luye Pharma Group Ltd.74 studiesSame company
Something wrong?
- Shandong Boan Biotechnology Co., Ltd8 studies →Acquired — became part of Luye Pharma Group Ltd., Feb 17, 2020 · source ↗
Something wrong?
- Nanjing Luye Sike Pharmaceutical Co., Ltd.5 studies →Acquired — became part of Luye Pharma Group Ltd., 2007 · source ↗
Something wrong?
- Shandong Luye Pharmaceutical Co., Ltd.4 studies →Subsidiary
Something wrong?
- Nanjing Sike Pharmaceutical Co., Ltd.3 studies →Acquired — became part of Luye Pharma Group Ltd., 2007 · source ↗
Something wrong?
Focus areas
Conditions Luye Pharma Group Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 94. Browse all 94 →
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1203 in Advanced Solid Tumors.RecruitingNCT07876609Phase 1
Sponsor listed in the registry: Shandong Boan Biotechnology Co., Ltd · First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd.
- Safety and Efficacy of BA1302 in Patients With Advanced Solid TumorsRecruitingNCT06596915Phase 1
Sponsor listed in the registry: Shandong Boan Biotechnology Co., Ltd · First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd.
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.RecruitingNCT06927349Phase 1
Sponsor listed in the registry: Shandong Boan Biotechnology Co., Ltd · First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd.
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid TumorsRecruitingNCT05650242Phase 1
Sponsor listed in the registry: Shandong Boan Biotechnology Co., Ltd · First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd.
- Mass Balance Study of [14C] LPM3770164 in Healthy ParticipantsNot yet recruitingNCT07516899Phase 1
- A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With SchizophreniaNot yet recruitingNCT07396870Phase 2
- LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS MutationNot yet recruitingNCT07391566Phase 1/2
- To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese SubjectsEnrolling by invitationNCT07371065Phase 1
- A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020RecruitingNCT07230652Phase 1
- A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017Not yet recruitingNCT06980207Phase 1
- Effect of Food and Age on the Pharmacokinetics of LY03017Not yet recruitingNCT06793995Phase 1
- Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaRecruitingNCT06731868Phase 1/2
- Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCRecruitingNCT06496048Phase 3
- Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic SurgeryRecruitingNCT06467409Phase 2
- To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release TabletsNot yet recruitingNCT06426485Phase 4
- A Study of BA1202 in Patients With Advanced Solid TumorsRecruitingNCT05909241Phase 1
Sponsor listed in the registry: Shandong Boan Biotechnology Co., Ltd · First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd.
- Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid TumorsEnrolling by invitationNCT05865925Phase 1/2
- First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.RecruitingNCT06240546Phase 1
- Study of LY01610 in Patients With Recurrent Small Cell Lung CancerRecruitingNCT06128837Phase 3
- Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mgNot yet recruitingNCT05856630Phase 1
- A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous InjectionCompletedNCT06095427Phase 1
Sponsor listed in the registry: Shandong Boan Biotechnology Co., Ltd · First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd.
- A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06022861Phase 3
Sponsor listed in the registry: Shandong Boan Biotechnology Co., Ltd · First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd.
- A Study of LY03015 in Healthy Chinese and Caucasian Adult SubjectsCompletedNCT07671833Phase 1
- A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.CompletedNCT05970510Phase 3
- A Food Effect Study of LY03020 in Healthy SubjectsActive, not recruitingNCT07292233Phase 1
- Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)Active, not recruitingNCT07236476Phase 2
- A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy SubjectsCompletedNCT06556966Phase 1
- Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release TabletsCompletedNCT06474650Phase 1
- Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy SubjectsCompletedNCT06216054Phase 1
- Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors PatientsCompletedNCT04638491Phase 1
- A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017Status unknownNCT06388551Phase 1
- Comparative Efficacy, Safety, PK, and Immunogenicity StudyActive, not recruitingNCT05853354Phase 3
- Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung CancerCompletedNCT04381910Phase 2
- Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT05321602Phase 1
- A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy SubjectsCompletedNCT05238701Phase 1
- Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal SurgeryCompletedNCT06204120Phase 2
- Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast CancerCompletedNCT06098599Phase 1
- Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)CompletedNCT05853341Phase 1
- A Dose-escalation Study of LPM3480392 in Chinese Healthy SubjectsCompletedNCT05862974Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PDCompletedNCT04630860Phase 1
- Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®CompletedNCT05140512Phase 1
- Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®CompletedNCT05110170Phase 3
- An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy SubjectsCompletedNCT05857449Phase 1
- A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PDCompletedNCT04571164Phase 3
- Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid TumorsCompletedNCT04088604Phase 1
- Relative Bioavailability of LY03010 Compared to Listed DrugCompletedNCT04922593Phase 1
- A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)CompletedNCT04853407Phase 3
- Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male SubjectsCompletedNCT05110118Phase 1
Sponsor listed in the registry: Shandong Boan Biotechnology Co., Ltd · First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd.
- A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for FractureStatus unknownNCT05060406Phase 3
- Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®CompletedNCT04563936Phase 3